Abstract

Flumazenil (Anexate - Roche) is the first benzodiazepine receptor antagonist to be marketed. The i.v. injection is licenced for termination of general anaesthesia induced or maintained with benzodiazepines, for the reversal of benzodiazepine sedation in short diagnostic or therapeutic procedures, and in intensive care. We discuss the value of flumazenil in these situations.